TFS Advances Neuroscience Research with Data-Driven Innovations and AI
By Anne-Marie Nagy
VP, Head of Internal Medicine & Neuroscience
In a recent interview with BioStock, Dr. Anne-Marie Nagy, Head of Internal Medicine and Neuroscience at TFS HealthScience, shared insights on how the company is leveraging data-driven strategies to tackle the challenges of neuroscience research. Read the full BioStock interview here.
TFS HealthScience is making significant strides in neuroscience drug development by leveraging data-driven insights, artificial intelligence (AI), and decentralized clinical trials (DCTs). As a global contract research organization (CRO), TFS provides expertise across multiple therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology.
During the interview, Dr. Anne-Marie Nagy, Head of Internal Medicine & Neuroscience at TFS HealthScience, highlights the complexities of neuroscience research and how TFS is addressing these challenges:
“Neuroscience is a fast-evolving field with immense potential, yet it carries a high risk of failure due to the intricate nature of neurological diseases and the subjectivity of clinical endpoints. Our role is to enhance trial efficiency, optimize data collection, and reduce risks using cutting-edge technologies.”
The Power of Data-Driven Insights and Biobanks in Advancing Neuroscience in the Nordics
With its headquarters in Lund, Sweden, TFS has a unique advantage in accessing Nordic health registries and biobanks. The Nordic healthcare system provides an extensive longitudinal data infrastructure, where individuals’ health records are linked from birth to death via national registries.
This allows for in-depth risk factor analysis for neurodegenerative diseases such as Alzheimer’s, helping researchers develop better treatment strategies. Additionally, the Nordic region’s strong biobank culture supports advanced genetic research, enabling more precise clinical trial designs and patient selection.
“Our ability to tap into high-quality Nordic data enables us to conduct more robust, data-driven neuroscience trials, leading to better patient outcomes,” Dr. Nagy explains.
Overcoming Challenges in Neuroscience Clinical Trials
Despite advancements, neuroscience trials face major challenges, particularly in the Nordics. These include:
- Limited patient populations, making recruitment more difficult.
- Higher trial costs compared to regions like Eastern Europe.
- Underreported trials, often due to resource constraints or regulatory complexities.
TFS actively supports drug developers in navigating these challenges by offering regulatory expertise, transparent data reporting, and trial optimization strategies. By ensuring compliance and efficiency, TFS helps smaller biotech firms bring their innovations to market.
“With our deep understanding of regulatory frameworks and market conditions, we assist sponsors in overcoming hurdles, ensuring ethical and efficient clinical trials,” says Dr. Nagy.
AI-Driven Trial Optimization: Reducing Risk and Enhancing Efficiency
A significant hurdle in neuroscience trials is the heterogeneity of patient populations and the lack of reliable clinical endpoints. This often results in high placebo responses and inconclusive findings. TFS tackles this issue by integrating AI-powered analytics to streamline data collection and trial management.
TFS employs an AI-driven clinical trial platform through its preferred partner, Medidata, allowing for real-time data monitoring, anomaly detection, and rapid course correction. This ensures data accuracy and enhances trial efficiency.
“AI enables us to detect data inconsistencies instantly, improving trial outcomes while accelerating drug development timelines,” Dr. Nagy notes.
Decentralized Trials: Expanding Access and Improving Patient Retention
A growing trend in neuroscience research is the shift towards decentralized clinical trials (DCTs). These trials leverage digital technologies—such as wearable devices and remote monitoring—to reduce hospital visits, enhance patient recruitment, and improve data accuracy.
For neurological disorders, where patients may have mobility limitations or require long-term monitoring, DCTs provide a patient-friendly approach that increases compliance and diversity in trials. Additionally, regulatory agencies increasingly favor real-world data collection, making DCTs a crucial component of modern neuroscience research.
“Decentralized trials improve patient access and engagement while reducing costs. This is a game-changer for neuroscience drug development,” explains Dr. Nagy.
The Future of Neuroscience Research
As neurodegenerative diseases like Alzheimer’s and Parkinson’s continue to rise, the demand for effective treatments is more urgent than ever. TFS’s commitment to leveraging data-driven insights, AI, and decentralized trials positions it at the forefront of neuroscience innovation.
By collaborating with leading academic institutions, patient advocacy organizations, and industry experts, TFS is driving innovation in neuroscience clinical trials. With expertise in biomarker validation, patient recruitment, and adaptive trial strategies, TFS is dedicated to accelerating the development of personalized therapies that address the complexities of neurological disorders.
Discover how TFS HealthScience is advancing neuroscience research through cutting-edge data strategies and AI-driven trial optimization. Contact us today to learn more.
About the Author
Anne-Marie Nagy
Anne-Marie joined TFS in September 2021 as Vice President, Head of Internal Medicine and Neuroscience and is responsible for supporting the project delivery of all internal medicine and neurology programs. Within her role, Anne-Marie manages a global team of experts ranging from physicians to clinical specialists delivering full-service clinical development programs and services for pharmaceutical and biotechnology customers.
Connect with Us
Contact us today to discover how TFS can be your strategic CRO partner in clinical development.
Learn More About Our Neuroscience Expertise
Rethinking Clinical Operations: A Smarter, Faster Playbook for Trial Success
Rare Neurological Disease Trials: Smarter Design with Natural History, External Controls, and Real-World Evidence
